STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2322 by analyst upside · 2026-08-14
AMRX
Amneal Pharmaceuticals, Inc.
Healthcare · Market Cap $6B · P/E 36.7x
ANALYST PRICE TARGET
+20.2%
implied upside to consensus target
Current Price $17.27
Consensus Target $20.75
Bull Target $25.0
Bear Target $16.0
Analysts Covering 4
ANALYST CONSENSUS - STRONG BUY
Strong Buy
2
Buy
2
Hold
0
Sell
0
52-Week Low $9.15
52-Week High $19.26
YTD Return +36.4%
FUNDAMENTALS
Market Cap $6B
P/E Ratio (TTM) 36.7x
Forward P/E 14.6x
EPS (TTM) $0.47
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $3.1B
Profit Margin 5.0%
52-WEEK RANGE
52-Week Low $9.15
52-Week High $19.26
Current Price $17.27
Bear Target $16.0
Bull Target $25.0
● Now $17.27 ● Target $20.75
TRADING DATA
Avg Volume 2.0M
YTD Return +36.4%
Analyst Count 4
Consensus Strong Buy
Upside to Target +20.2%
Last Updated 2026-08-14

ANALYST SUMMARY

Amneal Pharmaceuticals, Inc. (AMRX) is currently trading at $17.27 with a Wall Street consensus price target of $20.75, implying potential upside of 20.2% over the next 12 months. 4 analysts currently cover AMRX, with a consensus rating of Strong Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $25.0, while the most cautious has a target of $16.0.

AMRX operates in the Healthcare sector with a market capitalisation of $6B. The stock is up 36.4% year-to-date and is currently trading near the upper end of its 52-week range of $9.15 – $19.26.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for AMRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays - Reiterated
Overweight → Overweight 2026-05-20 Building track record
UBS ● Initiated
Buy 2026-04-17 33% win rate (6 calls)
Truist Securities - Reiterated
Buy → Buy 2026-03-02 Building track record
Barclays ● Initiated
Overweight 2025-12-09 Building track record
Piper Sandler reit
Overweight → Overweight 2025-10-31 14% win rate (7 calls)
JP Morgan - Reiterated
Overweight → Overweight 2025-09-16 43% win rate (7 calls)
Barclays - Reiterated
Overweight → Overweight 2025-03-03 Building track record
JP Morgan ↑ Upgrade
Neutral → Overweight 2025-02-24 43% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
59
out of 100
Coverage depth
12/30
Consensus clarity
20/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →